Why Are Cingulate Shares Trading Higher Today?
Portfolio Pulse from Vandana Singh
Cingulate Inc (NASDAQ:CING) shares are trading higher following the announcement of positive topline results from its Phase 3 adult trial of lead candidate, CTx-1301, for attention-deficit/hyperactivity disorder (ADHD). The data showed a significant trend in improving ADHD symptoms. The company plans to initiate its pivotal Phase 3 fixed-dose pediatric and adolescent study this month and a dose-optimization onset and duration trial in pediatric patients in August 2023. Assuming positive results, Cingulate plans to submit a New Drug Application for CTx-1301 in mid-2024.
July 11, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cingulate Inc's shares are trading higher following positive Phase 3 trial results for its ADHD drug, CTx-1301. Further trials are planned, and a New Drug Application is expected in mid-2024.
The positive results from the Phase 3 trial of CTx-1301 have led to an increase in Cingulate Inc's share price. The company's plans for further trials and a New Drug Application in mid-2024 suggest a positive outlook for the company, which is likely to continue to positively impact the share price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100